Laurie Stelzer
CIK 1644348 · Chief Financial Officer · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
9
Total Filings
48
Lifetime Open-Market Net
$172.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PMVP | Director | — | $1.11 | — | $0 | 6 | 2026-06-05 |
| MBX | Director | — | $35.51 | — | $0 | 2 | 2026-06-05 |
| SYRE | Director | — | $80.79 | — | $0 | 3 | 2026-05-29 |
| SION | Director | — | $35.92 | — | $0 | 1 | 2025-06-16 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2023-11-27 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Financial Officer | 102,312 | $58.70 | $6.01M | -$172.2K | 4 | 2023-08-10 |
| Surface Oncology, Inc. (SURF) Delisted | Director | — | $1.07 | — | $0 | 4 | 2022-06-10 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | EVP & Chief Financial Officer | 28,122 | $99.99 | $2.81M | $0 | 5 | 2022-03-11 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP, Chief Financial Officer | 126,167 | — | — | $344.8K | 22 | 2020-02-24 |
Recent Filings · Page 3 of 5
48 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-09 | PMVP | Grant (A) | — | $0 | EDGAR |
| 2021-04-02 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Mixed | +8,244 | -$331.5K | EDGAR |
| 2021-03-03 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | +6,660 | $0 | EDGAR |
| 2020-06-12 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-17 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-24 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +6,884 | -$98.4K | EDGAR |
| 2020-02-18 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +5,109 | -$57.0K | EDGAR |
| 2020-02-13 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +7,368 | -$77.9K | EDGAR |
| 2020-02-12 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-04 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +14,844 | -$159.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.